Plamen B.
- Country
- Bulgaria
- Department
- Department of Neurology diseases
Research Overview
- Evaluation of Long-Term Safety and Tolerability of Tavapadon in Patients with Parkinson's Disease: A 58-Week Open-Label Multinational Study
- Phase 3 Randomized, Double‑Blind Study of IMU‑838 (vidofludimus calcium) versus Placebo in Adults with Relapsing Multiple Sclerosis
- Efficacy, Safety, and Tolerability of Vidofludimus Calcium in Progressive Multiple Sclerosis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Data & Insights
Has run more than one trial at 34 of 157 partner sites.
Specializations
Multiple Sclerosis Research
The investigator specializes in various forms of multiple sclerosis, with particular focus on both progressive and relapsing forms of the condition. Their research encompasses brain atrophy assessment and innovative therapeutic approaches.
- Progressive Multiple Sclerosis (PMS)
- Relapsing-Remitting Multiple Sclerosis (RRMS)
- Brain Volume Analysis
The investigator utilizes advanced magnetic resonance imaging (MRI) techniques for disease monitoring and treatment evaluation.
Neurological Disorders
Research activities extend to other neurological conditions, with significant work in Parkinson's disease management and treatment development.
- Movement Disorders
- Long-term Treatment Evaluation
- Therapeutic Safety Assessment
The focus includes evaluation of novel therapeutic approaches for chronic neurological conditions.
Seizure Management
The investigator conducts research in seizure disorders, particularly focusing on rapid intervention strategies and long-term management approaches.
- Stereotypical Prolonged Seizures
- Emergency Seizure Treatment
- Pediatric and Adult Applications
Research includes evaluation of rapid-acting therapeutic interventions for acute seizure episodes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.